|
The pandemic pipeline
[Nature Biotech] - Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.A survey of various techniques used in Covid-19 treatment without companies' self promotion, or jurno distortions. Major points ...batches of the mRNA vaccine could reach clinics as early as 2021. This will be too late for the current pandemic. And given that no mRNA vaccine has ever been approved, mRNA-1273 faces numerous challenges in clinical development and manufacture before it has the possibility of being made available for global immunization. ...Approved small molecules are already in use off label as adjunct therapies for critically ill patients (like Fujifilm Toyama Chemical’s favipiravir), with several other experimental drugs (like Gilead’s remesdivir) under investigation. Repurposed monoclonal antibodies (mAbs) developed against previous coronaviruses, such as severe acute respiratory syndrome (SARS) virus and Middle Eastern respiratory syndrome (MERS) virus, promise passive immunity before vaccines come online. Somebody, probably, working on producing a batch of anti-Covid antibodies by animal immunization instead of the current primitive vampirism ...it is becoming increasingly clear that the biggest problem for drug and vaccine makers is not which therapeutic or vaccine platform to pursue. It is that conventional clinical development paths are far too lengthy and cumbersome to address the current public health threat. Several groups are now exploring how to retool the development process to find solutions. Covid-19 might be a blessing in disguise Posted by: g(r)omgoru 2020-03-25 |
| http://www.rantburg.com/poparticle.php?ID=566889 |